Floatz logo

Epoetin Alfa

Injury

Australian and New Zealand Intensive Care Research CentreUNKNOWNPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Injury cohort.

Asset / SponsorPhaseRating
Testosterone Undecylate
Craig Hospital
Phase 4BB
Tranexamic Acid
Daniel Nishijima, MD, MAS
Phase 3BB
Glucose, Anhydrous
Baskent University
Phase 4BB
Midazolam
Baskent University
Phase 4BB
Apsolol
Hamad Medical Corporation
Phase 4BB

View all 29 →

Same molecule, other indications

Epoetin Alfa is also rated in:

anemiaDormant
BBB
Indicative · Phase 4
79 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative · Phase 3
71 / 100
View asset →
precancerous conditionDormant
BB
Indicative · Phase 3
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →